The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.
about
Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis.Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies.Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.East Indian Sandalwood Oil (EISO) Alleviates Inflammatory and Proliferative Pathologies of Psoriasis.Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies.Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.Secukinumab for treating plaque psoriasis.Secukinumab (AIN-457) for the treatment of Psoriasis.Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.DFD-01: a novel topical formulation of betamethasone dipropionate for the treatment of extensive psoriasis.Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial.Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies.Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis.Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice.Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis.Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.The cost-effectiveness of blue-light therapy in the treatment of mild-to-moderate psoriasis.Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriSecukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial.Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
P2860
Q31013575-B8EDD407-DF2F-4DEE-97DD-CD8F447A5607Q33844447-504C53BF-A4F2-41FA-A407-3573DBE4CF55Q37295966-1D9F38A4-B0FD-40CF-9CF6-A03F4C02184BQ37432244-28A4B052-5A5E-4A91-9928-94B336489709Q37620900-5C1A6721-80D6-4814-9852-F1C964696FD1Q37703061-353BFCB7-3847-40B2-A788-C37B7FC9A47FQ38388241-29CFFCA1-C35A-4DD0-A498-5F5E816AAA82Q38421550-558DEAB2-FD1E-4B23-B5C3-358CBFC223BBQ38636359-8443BC46-C459-4A82-B5AC-6755C37B7520Q38662868-49992590-3E0C-4B5A-AC1F-8BE96F95E961Q38925574-4FC777EC-1089-499A-B132-88CB9FA37AD0Q39038227-3AEA4B1E-DD01-421C-9889-94AA0F44A8A0Q40164172-601F7C02-EB94-4139-8CB9-88C238466958Q46453213-9E18E03C-3A9D-44D2-947A-DA31D9CFA2C7Q47346793-06348800-B678-437A-B654-C7EE572614C7Q47375172-71C5886E-E04B-4322-B2D4-ECA7D034B523Q47901584-918D99CA-CCBE-468D-A3E4-733E7700FE5BQ47945421-DA148DE6-2111-4885-A98F-88AEC69A3183Q48331000-5BC71720-11F8-4388-B21E-E58EE70161BDQ48358207-5B1B542F-E377-40FC-B9E6-8C014A6BF33AQ48368354-31B5DEDF-B33C-41B6-A75A-3CD5E8C28D44Q50177487-D571721F-E68B-4097-86E4-79FAC3E1901BQ50193268-2EF31BF7-0192-434D-9A97-80A7B702F41EQ51359715-3CD66E96-F984-4C92-9E94-54E050744C78Q52922335-AF4019FF-F0E0-4B15-BFB4-37E85EFCED4FQ53172353-0E11CB72-9200-4387-A3A8-B73ACE7F8EEDQ53471047-4C42D11B-1310-4C39-AAD3-8868C1877966
P2860
The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The 5-point Investigator's Glo ...... s severity in clinical trials.
@ast
The 5-point Investigator's Glo ...... s severity in clinical trials.
@en
The 5-point Investigator's Global Assessment
@nl
type
label
The 5-point Investigator's Glo ...... s severity in clinical trials.
@ast
The 5-point Investigator's Glo ...... s severity in clinical trials.
@en
The 5-point Investigator's Global Assessment
@nl
prefLabel
The 5-point Investigator's Glo ...... s severity in clinical trials.
@ast
The 5-point Investigator's Glo ...... s severity in clinical trials.
@en
The 5-point Investigator's Global Assessment
@nl
P2093
P2860
P1476
The 5-point Investigator's Glo ...... is severity in clinical trials
@en
P2093
Charis Papavassilis
Judit Nyirady
Peter van de Kerkhof
Richard G B Langley
P2860
P356
10.3109/09546634.2013.865009
P577
2013-12-20T00:00:00Z